BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/12/2024 6:10:26 AM | Browse: 277 | Download: 1316
 |
Received |
|
2023-12-12 14:45 |
 |
Peer-Review Started |
|
2023-12-12 14:45 |
 |
First Decision by Editorial Office Director |
|
2024-01-09 04:43 |
 |
Return for Revision |
|
2024-01-09 04:43 |
 |
Revised |
|
2024-01-18 07:53 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2024-02-22 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2024-02-22 03:57 |
 |
Articles in Press |
|
2024-02-22 03:57 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2024-03-04 09:07 |
 |
Publish the Manuscript Online |
|
2024-03-12 06:10 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rui Zhu, Tian-Ze Chen, Meng-Ting Sun and Chun-Rong Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chun-Rong Zhu, DPhil, PhD, Associate Professor, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. zcr050311@163.com |
| Key Words |
Cadonilimab; Complete response; Bispecific antibodies; Recurrent or metastatic cervical cancer; Programmed death protein 1; Cytotoxic T-lymphocyte-associated antigen-4; Case report |
| Core Tip |
Advanced metastatic cervical cancer (MCC) has a poor prognosis and a low survival rate. The emergence of bispecific antibodies offers a novel treatment option for patients with MCC. Cadonilimab is a tetravalent bispecific antibody designed to simultaneously block the programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways while substantially reducing toxicities compared to combination therapy with PD-1 and CTLA-4 antibodies. We report the case of a patient with advanced MCC who achieved a complete response with cadonilimab monotherapy despite chemotherapy-induced grade IV myelosuppression. |
| Publish Date |
2024-03-12 06:10 |
| Citation |
Zhu R, Chen TZ, Sun MT, Zhu CR. Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report. World J Clin Cases 2024; 12(8): 1510-1516 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i8/1510.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i8.1510 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.